Lineage Cell Therapeutics (LCTX) Non Operating Income (2010 - 2026)

Lineage Cell Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at $405000.0 for Q1 2026.

• In Q1 2026, Non Operating Income fell 82.85% year-over-year to $405000.0; the TTM figure through Mar 2026 stood at -$22.9 million (down 551.53% YoY), while the FY2025 annual figure was -$32.0 million, down 1205.94% from the prior year.
• Non Operating Income for Q1 2026 stood at $405000.0, down from $2.2 million in the prior quarter.
• The five-year high for Non Operating Income was $2.4 million in Q1 2025, with the low at -$26.0 million in Q3 2025.
• The 5-year median for Non Operating Income is $405000.0 (2026), against an average of -$1.1 million.
• Peak annual rise in Non Operating Income reached 2193.2% in 2025, while the deepest fall reached 6640.55% in 2025.
• Lineage Cell Therapeutics' Non Operating Income stood at $277000.0 in 2022, then surged by 494.95% to $1.6 million in 2023, then increased by 12.86% to $1.9 million in 2024, then climbed by 16.13% to $2.2 million in 2025, then plunged by 81.25% to $405000.0 in 2026.
• Business Quant data shows LCTX's Non Operating Income at $405000.0 in Q1 2026, $2.2 million in Q4 2025, and -$26.0 million in Q3 2025.